Results 1 to 10 of about 11,803 (177)

Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement [PDF]

Cancer Imaging, 2023
Background Although some studies have assessed the correlation between computed tomography (CT) features and anaplastic lymphoma kinase (ALK) rearrangement in patients with non-small-cell lung cancer (NSCLC), few have focused on early-stage patients. The
Xiaoming Hou, Han Chen, You Liu, Sandong Gong, Meizi Zhudai, Leilei Shen   +5 more
doaj   +2 more sources

Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report [PDF]

Frontiers in Oncology, 2022
Next-generation sequencing technology has enabled the identification of fusion partners of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer, and various ALK fusion partners have been confirmed.
Hui Li, Yixiao Deng, Bin Chen, Yajie Xiao, Jie Yang, Qionghui Liu, Gengpeng Lin   +6 more
doaj   +2 more sources

Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib [PDF]

Frontiers in Pharmacology
BackgroundAnaplastic lymphoma kinase (ALK) rearrangement is a crucial oncogenic driver in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (ALK-TKIs) represent the primary therapeutic option for advanced NSCLC patients with ALK ...
Yinyin Xue, Yinyin Xue, Wen Li, Wen Li, Kaili Huang, Kaili Huang, Qinghua Zhou, Qinghua Zhou, Qiang Wu, Qiang Wu   +9 more
doaj   +2 more sources

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study [PDF]

Respiratory Research, 2022
Background Timely identification of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement status in patients with non-small cell lung cancer (NSCLC) is essential for tyrosine kinase inhibitors (TKIs ...
Xueyun Tan, Yuan Li, Sufei Wang, Hui Xia, Rui Meng, Juanjuan Xu, Yanran Duan, Yan Li, Guanghai Yang, Yanling Ma, Yang Jin   +10 more
doaj   +2 more sources

Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study [PDF]

Cancer Communications
Background Anaplastic lymphoma kinase (ALK) test in advanced non‐small cell lung cancer (NSCLC) can help physicians provide target therapies for patients harboring ALK gene rearrangement.
Lin Li, Wencai Li, Chunyan Wu, Yanfeng Xi, Lei Guo, Yuan Ji, Lili Jiang, Ji Li, Jingping Yun, Gang Chen, Yuan Li, Yueping Liu, Dianbin Mu, Yuchen Han, Leina Sun, Qingxin Xia, Xiaodong Teng, Nanying Che, Wei Wu, Xueshan Qiu, Chao Liu, Xiaochu Yan, Daiqiang Li, Zhihong Zhang, Zhe Wang, Yujun Li, Zheng Wang, Lingchuan Guo, Xiu Nie, Jingshu Geng, Jianhua Zhou, Jianming Ying   +31 more
doaj   +2 more sources

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma [PDF]

Thoracic Cancer, 2021
Background The prognostic significance of ALK rearrangement is still contradictory. Here, we aimed to investigate the clinical characteristics and outcomes of lung adenocarcinoma patients with ALK rearrangement, and analyze whether these patients ...
Huan Zhang, Guangyao Shan, Benjie Cai, Guoshu Bi, Zhencong Chen, Jiaqi Liang, Valeria Besskaya, Yuansheng Zheng, Weigang Guo, Lin Wang, Songtao Xu, Cheng Zhan   +11 more
doaj   +2 more sources

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report [PDF]

Frontiers in Oncology, 2021
Anaplastic lymphoma kinase (ALK) rearrangement occurs in 5% to 8% of patients with non-small cell lung cancer (NSCLC). More than 90 different ALK fusion partners have been discovered in NSCLC patients, and ALK tyrosine kinase inhibitors (TKIs) such as ...
Chunlai Feng, Rong Zhou, Feng Liu, Tingting Wang, Sisi Liu, Yang Shao   +5 more
doaj   +2 more sources

Sensitivity to ALK-Directed Therapy in Osteosarcoma With an Acquired ALK Rearrangement. [PDF]

JCO Precis Oncol, 2023
Ordulu Z, Giunta P, Hung WT, Hung YP, Simon J, Fintelmann FJ, Lennerz JK, Naxerova K, Cote GM.   +8 more
europepmc   +3 more sources

PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer. [PDF]

Molecular oncology, 2023
Treatment with anaplastic lymphoma kinase (ALK) inhibitors significantly improves outcome for non-small-cell lung cancer (NSCLC) patients with ALK-rearranged tumors. However, clinical resistance typically develops over time and, in the majority of cases, resistance mechanisms are ALK-independent.
Talwelkar, Sarang S., Mäyränpää, Mikko I., Schüler, Julia, Linnavirta, Nora, Hemmes, Annabrita, Adinolfi, Simone, Kankainen, Matti, Sommergruber, Wolfgang, Levonen, Anna‐Liisa, Räsänen, Jari, Knuuttila, Aija, Verschuren, Emmy W., Wennerberg, Krister   +12 more
  +7 more sources

Lorlatinib in ALK-Rearranged Lung Cancer [PDF]

Cancer Cell, 2021
Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.
Shelley, Kuang, Natasha B, Leighl
openaire   +2 more sources